Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Follistatin 315

Activin-Binding Protein, FSH-Suppressing Protein, FST-315, FS-315

Quick Stats
Studies 14
Trials 93
Completed PHASE4 INTERVENTIONAL NCT02382471

Assessing the Effects of Omega-3 Supplementation on Some Serum BDNF، Follistatin، Irisin Levels in Men With CAD

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

The aim of this study is the comparison between the effects of supplementation with omega 3 or placebo for 8 weeks in serum level of BDNF، Follistatin، Irisin in patients with cardiovascular disease.

Detailed Description

The aim of this study is the comparison between the effects of supplementation with omega 3 or placebo for 8 weeks in serum level of BDNF، Follistatin، Irisin in patients with cardiovascular disease. In this randomized, double-blind clinical trial, placebo-controlled, single-center, and phase two trials, 42men aged 45-65 years with Coronary Artery Disease are enrolled in the study from Tehran Heart Center. After signing informed consent all individuals complete a general information form , 24-hour food recall for 3 days will be taken from the participants at the beginning and the end of the study,. Selected samples are randomly classified into 2 blocks of groups receiving supplement and placebo. The supplement group, will receive 4 g/day omega 3 fatty acid for 8 weeks and the placebo group will also receive placebo (containing 4 g of edible paraffin) (similar in terms of color, shape and size). Patients are recommended to sustain their diets and medication dose (s) during the study and also advised to maintain a constant level of physical activity. Blood samples will be collected after 8-12 hours fasting and anthropometric variables, biochemical parameters and physical activity before and after the trial will be measured.

Interventions

Name: Omega-3
Type: DIETARY_SUPPLEMENT
Description: 4 cap 1 g Omega-3 per day for 2 months
Name: Placebo
Type: DIETARY_SUPPLEMENT
Description: 4 cap 1 g Placebo(paraffin) per day for 2 months

Primary Outcomes

Measure: Serum Irisin
TimeFrame: Change from baseline at 2 months
Description:
Measure: Serum Brain-Derived Neurotrophic Factor(BDNF)
TimeFrame: Change from baseline at 2 months
Description:
Measure: Serum Follistatin
TimeFrame: Change frome baseline at 2 months
Description:
Measure: Serum Myostatin
TimeFrame: Change from baseline at 2 months
Description:

Trial Information

NCT ID

NCT02382471

Status

Completed

Study Type

INTERVENTIONAL

Phases

PHASE4

Sponsor

Tehran University of Medical Sciences

Last Updated

December 15, 2025

Related Peptides